Aequus Pharmaceuticals Inc.
AQSZF
$0.004
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.44% | 45.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.44% | 45.91% | |||
| Cost of Revenue | 17.38% | 0.19% | |||
| Gross Profit | -9.43% | 89.87% | |||
| SG&A Expenses | -51.88% | -29.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.07% | -25.97% | |||
| Operating Income | 72.18% | 45.41% | |||
| Income Before Tax | -188.88% | 65.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -188.88% | 65.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -188.88% | 65.48% | |||
| EBIT | 72.18% | 45.41% | |||
| EBITDA | -- | 45.52% | |||
| EPS Basic | -183.33% | 64.71% | |||
| Normalized Basic EPS | 64.29% | 33.33% | |||
| EPS Diluted | -183.33% | 64.71% | |||
| Normalized Diluted EPS | 64.29% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||